Abcellera Biologics Inc (ABCL) Stock Price, Quote & News

Company Profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research coll...

Industry: Biotechnology

Sector: Healthcare

Phone: 604 559 9005

Website: www.abcellera.com

Address:

150 West 4th Ave, Vancouver, Canada

Stocktradesmoon Jan. 15 at 11:12 PM

$ABCL 👀

0 · Reply

Ed_Ng Jan. 15 at 8:54 PM

$ABCL don't spread fake info

0 · Reply

Stocktradesmoon Jan. 15 at 7:34 PM

$ABCL $ABCL Someone's keepin' on pickin' up 5,000 at a time... Who the hell are you..

0 · Reply

Stocktradesmoon Jan. 15 at 7:32 PM

$ABCL

0 · Reply

Ed_Ng Jan. 15 at 7:18 PM

$ABCL I didn't give the exact day it will drop to 2, but it will. It did drop to 1.9 before when everyone kept saying it was impossible. I only said the true and it did happen.

0 · Reply

Cassek86 Jan. 15 at 7:16 PM

$ABCL You always twist your statements here to make yourself seem right. For months you've been announcing a drop to $2, which never happened.

0 · Reply

Ed_Ng Jan. 15 at 7:11 PM

$ABCL it's not failed. So you don't realize 7$ drop today after the conference was not blood bath? It's 7% my friend. Now it's just slowly go back up with low volume and will definitely drop later

0 · Reply

Cassek86 Jan. 15 at 6:50 PM

$ABCL The stock has shown relative strength lately, despite all the doomsday predictions. Your bloodbath prediction has failed to materialize once again.

0 · Reply

DragonAlgo Jan. 15 at 6:15 PM

🐉 $ABCL CALL — DragonAlgo® Signal Contract: ABCL CALL Expiry: 2026-04-17 | Strike: $5.00 | Type: CALL Option Plan (premium): Entry: $0.62 Stop: $0.45 TP1: $0.81 TP2: $1.06 TP3: $1.50 System-defined risk profile. 🔗 https://dragonalgo.com

0 · Reply

Ed_Ng Jan. 15 at 3:28 PM

$ABCL hope you listen. Chart and historical data never lie

0 · Reply

AbCellera Biologics Inc. (ABCL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 9:00 AM EST - 3 days ago

AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause

Dec 18, 2025, 9:00 AM EST - 4 weeks ago

AbCellera and Bruker Reach Global Settlement of Patent Litigation

Dec 8, 2025, 4:05 PM EST - 5 weeks ago

AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

Dec 8, 2025, 1:37 PM EST - 5 weeks ago

AbCellera Biologics Inc. (ABCL) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Nov 22, 2025, 12:23 AM EST - 7 weeks ago

AbCellera Biologics Inc. (ABCL) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 10, 2025, 9:00 AM EST - 2 months ago

AbCellera Appoints Dr. Stephen Quake to its Board of Directors

Nov 7, 2025, 7:16 PM EST - 2 months ago

AbCellera Biologics Inc. (ABCL) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 4:05 PM EST - 2 months ago

AbCellera Reports Q3 2025 Business Results

Oct 7, 2025, 4:05 PM EDT - 3 months ago

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

Oct 6, 2025, 7:35 AM EDT - 3 months ago

AbCellera Biologics: Entering Growth Phase After A Pause

Sep 29, 2025, 4:05 PM EDT - 3 months ago

AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025

Sep 10, 2025, 9:07 AM EDT - 4 months ago

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

Aug 27, 2025, 9:00 AM EDT - 5 months ago

AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575

Aug 12, 2025, 4:05 PM EDT - 5 months ago

AbCellera to Participate at Upcoming Investor Conferences in September

Aug 7, 2025, 7:48 PM EDT - 5 months ago

AbCellera Biologics Inc. (ABCL) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:05 PM EDT - 5 months ago

AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms

Jul 7, 2025, 4:05 PM EDT - 6 months ago

AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025

May 30, 2025, 1:00 PM EDT - 8 months ago

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

May 14, 2025, 5:00 PM EDT - 8 months ago

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

May 12, 2025, 3:30 PM EDT - 8 months ago

AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

May 9, 2025, 7:30 PM EDT - 8 months ago

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

May 8, 2025, 10:33 PM EDT - 8 months ago

AbCellera Biologics Inc. (ABCL) Q1 2025 Earnings Call Transcript

May 8, 2025, 4:05 PM EDT - 9 months ago

AbCellera Reports Q1 2025 Business Results

Apr 29, 2025, 3:00 PM EDT - 9 months ago

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

Apr 8, 2025, 4:05 PM EDT - 10 months ago

AbCellera to Participate at Upcoming Investor Conferences in May and June

Apr 3, 2025, 4:05 PM EDT - 10 months ago

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

Mar 25, 2025, 4:30 PM EDT - 10 months ago

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

Feb 27, 2025, 11:26 PM EST - 11 months ago

AbCellera Biologics Inc. (ABCL) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 4:05 PM EST - 11 months ago

AbCellera Reports Full Year 2024 Business Results

Feb 11, 2025, 4:05 PM EST - 1 year ago

AbCellera to Participate at Upcoming Investor Conferences in March

Jan 21, 2025, 4:05 PM EST - 1 year ago

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

Jan 13, 2025, 9:00 AM EST - 1 year ago

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

Dec 23, 2024, 4:39 PM EST - 1 year ago

AbCellera Biologics: Still A Concept Stock

Nov 21, 2024, 4:05 PM EST - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in December and January

Nov 7, 2024, 10:05 AM EST - 1 year ago

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

Nov 4, 2024, 7:22 PM EST - 1 year ago

AbCellera Biologics Inc. (ABCL) Q3 2024 Earnings Call Transcript

Nov 4, 2024, 4:05 PM EST - 1 year ago

AbCellera Reports Q3 2024 Business Results

Oct 22, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in November 2024

Oct 14, 2024, 12:04 PM EDT - 1 year ago

AbCellera: A Platform To Pipeline Transition

Oct 4, 2024, 9:00 AM EDT - 1 year ago

AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024

Sep 26, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024

Aug 29, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in September

Aug 23, 2024, 4:43 AM EDT - 1 year ago

AbCellera: A Waiting Game With High Uncertainty

Aug 20, 2024, 9:45 AM EDT - 1 year ago

This Globant Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

GLOB AVDX LRN PGRU

Aug 6, 2024, 4:05 PM EDT - 1 year ago

AbCellera Reports Q2 2024 Business Results

Jul 31, 2024, 9:00 AM EDT - 1 year ago

AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines

Jun 25, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024

May 28, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024

May 7, 2024, 11:00 PM EDT - 1 year ago

AbCellera Biologics Inc. (ABCL) Q1 2024 Earnings Call Transcript

Stocktradesmoon Jan. 15 at 11:12 PM

$ABCL 👀

0 · Reply

Ed_Ng Jan. 15 at 8:54 PM

$ABCL don't spread fake info

0 · Reply

Stocktradesmoon Jan. 15 at 7:34 PM

$ABCL $ABCL Someone's keepin' on pickin' up 5,000 at a time... Who the hell are you..

0 · Reply

Stocktradesmoon Jan. 15 at 7:32 PM

$ABCL

0 · Reply

Ed_Ng Jan. 15 at 7:18 PM

$ABCL I didn't give the exact day it will drop to 2, but it will. It did drop to 1.9 before when everyone kept saying it was impossible. I only said the true and it did happen.

0 · Reply

Cassek86 Jan. 15 at 7:16 PM

$ABCL You always twist your statements here to make yourself seem right. For months you've been announcing a drop to $2, which never happened.

0 · Reply

Ed_Ng Jan. 15 at 7:11 PM

$ABCL it's not failed. So you don't realize 7$ drop today after the conference was not blood bath? It's 7% my friend. Now it's just slowly go back up with low volume and will definitely drop later

0 · Reply

Cassek86 Jan. 15 at 6:50 PM

$ABCL The stock has shown relative strength lately, despite all the doomsday predictions. Your bloodbath prediction has failed to materialize once again.

0 · Reply

DragonAlgo Jan. 15 at 6:15 PM

0 · Reply

Ed_Ng Jan. 15 at 3:28 PM

$ABCL hope you listen. Chart and historical data never lie

0 · Reply

Ed_Ng Jan. 15 at 3:20 PM

$ABCL I'm always right,!

0 · Reply

DeMampCamp Jan. 15 at 3:00 PM

$ABCL This is a head fake to get the short timers to dump, which a lot will! I fully expect this stock to move back above $5 short term at minimum

3 · Reply

Plutten1973 Jan. 15 at 2:44 PM

$ABCL A normal Abcelleraday again Good news , everything goes as planned and we go down hahahahaha Im happy i have so much patience!

0 · Reply

tranq19 Jan. 15 at 12:39 PM

$ABCL pipeline starting to snowball! 4 internal programs, 2 more this year if you include 635 for oncology, 3 more next year. During 2027 they’ll have 8-9 programs, results rolling in on a regular basis, and royalties should start kicking in as well

1 · Reply

JennyRowes Jan. 15 at 6:23 AM

$ABCL listened to JPM talk. Wow! All three execs are sharp, honest, and command respect. They stick to just facts, but the facts are awesome. This could take time but really feels like a winner

4 · Reply

UncleTomFlorida Jan. 15 at 4:07 AM

$ABCL

0 · Reply

UncleTomFlorida Jan. 15 at 3:29 AM

$ABCL Conference transcript https://email-st.seekingalpha.com/click/43542372.539/aHR0cHM6Ly9zZWVraW5nYWxwaGEuY29tL2FjY291bnQvZW1haWwtYXV0aD9zYWlsdGhydV9hdXRoX3BhcmFtPTYwNzI5ODc4OjE3Njg0NDM0ODM6NDNjZWFmZTdlZDRkOGQxNzRiNDVlNDQ0MWIzZTc1NTMmcmVmPWh0dHBzOi8vc2Vla2luZ2FscGhhLmNvbS9hcnRpY2xlLzQ4NTk5NTYtYWJjZWxsZXJhLWJpb2xvZ2ljcy1pbmMtYWJjbC1wcmVzZW50cy1hdC00NHRoLWFubnVhbC1qLXAtbW9yZ2FuLWhlYWx0aGNhcmUtY29uZmVyZW5jZT9wb3NpdGlvbiUzRHJ0YV9hbmFseXNpc19wb3B1bGFyX21haW5fMF90aXRsZSZ1dG1fc291cmNlPXNlZWtpbmdfYWxwaGEmbWFpbGluZ2lkPTQzNTQyMzcyJnNlcmlhbD00MzU0MjM3Mi41MzkmdXRtX3Rlcm09NDM1NDIzNzIuNTM5Jm1lc3NhZ2VpZD0yODAwJnNvdXJjZT1lbWFpbF8yODAwJnV0bV9jYW1wYWlnbj1ydGEtc3RvY2stYXJ0aWNsZQ/66a5c2d336f9de73b004fef7B49c6e457 hope this link works

0 · Reply

UncleTomFlorida Jan. 15 at 3:07 AM

$ABCL

0 · Reply

UncleTomFlorida Jan. 15 at 3:02 AM

$ABCL I think one key takeaway from JPM HLTH CONF presentation is that ABCL635 will eventually go into Phase2 Clinical Trials for oncology VMS while continuing through Phase 3 for menopause VMS side effects. We don’t know at this point just what kind of cancer will be targeted. Another is that ABCL is administered subcutaneously like the current crop of semaglutides, aka Ozempic, Wegovy.

0 · Reply

Kaykay610 Jan. 15 at 2:23 AM

$ABCL if they can show efficacy with a monthly injection they will beat the competition on convenience alone.(with Veozah you need to take weekly blood test to avoid liver toxicity issues and take daily). Once daily approved drugs is the option for now and 635 will swoop in and snatch all those patients and insurers will gravitate to a treatment with less side effects!!!

3 · Reply

UncleTomFlorida Jan. 15 at 1:36 AM

$ABCL JPM HEALTH CONFERENCE PRESENTATION: https://d18rn0p25nwr6d.cloudfront.net/CIK-0001703057/40de8a76-5969-4b19-b018-234b15e8cf95.pdf

0 · Reply

Stocktradesmoon Jan. 15 at 1:33 AM

$ABCL T-Cell engager perhaps? 🤔

0 · Reply

Market Cap	1.28B
Revenue (ttm)	28.83M
Net Income (ttm)	-162.86M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-564.90%
Debt to Equity Ratio	0.00

Volume	5,316,300
Avg Vol	4,401,528
Day's Range	N/A - N/A
Shares Out	299.34M
Stochastic %K	72%
Beta	0.73
Analysts	Strong Sell
Price Target	$9.00